

# The United States of America



## CERTIFICATE OF REGISTRATION PRINCIPAL REGISTER

*The Mark shown in this certificate has been registered in the United States Patent and Trademark Office to the named registrant.*

*The records of the United States Patent and Trademark Office show that an application for registration of the Mark shown in this Certificate was filed in the Office; that the application was examined and determined to be in compliance with the requirements of the law and with the regulations prescribed by the Director of the United States Patent and Trademark Office; and that the Applicant is entitled to registration of the Mark under the Trademark Act of 1946, as Amended.*

*A copy of the Mark and pertinent data from the application are part of this certificate.*

*This registration shall remain in force for TEN (10) years, unless terminated earlier as provided by law, and subject to compliance with the provisions of Section 8 of the Trademark Act of 1946, as Amended.*



*Nicholas P. Galbraith*

*Acting Director of the United States Patent and Trademark Office*

**Int. Cl.: 1**

**Prior U.S. Cls.: 1, 5, 6, 10, 26 and 46**

**Reg. No. 2,450,940**

**United States Patent and Trademark Office**

**Registered May 15, 2001**

**TRADEMARK  
PRINCIPAL REGISTER**

**714X**

**CENTRE EXPERIMENTAL DE RECHERCHES  
BIOLOGIQUES DE L'ESTRIE INC. (CANADA  
CORPORATION)  
5260, MILLS STREET  
ROCK FOREST, PROVINCE OF QUEBEC, CANADA  
J1N 3B6**

**FOR: SOLUTION TO BE USED IN THE TREAT-  
MENT OF DEGENERATIVE DISEASES OR AS AN  
IMMUNOMODULATOR, TO BE INTRODUCED  
INTO THE BODY EITHER BY WAY OF PERINOD-**

**ULAR INJECTION OR THROUGH THE USE OF AN  
ULTRASONIC NEBULIZER, IN CLASS 1 (U.S. CLS. 1,  
5, 6, 10, 26 AND 46).**

**FIRST USE 9-12-1975; IN COMMERCE 9-12-1975.**

**SER. NO. 76-027,034, FILED 4-17-2000.**

**KELLEY WELLS, EXAMINING ATTORNEY**

The  
United  
States  
of  
America



**The Director of the United States  
Patent and Trademark Office**

*Has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law.*

*Therefore, this*

**United States Patent**

*Grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America for the term set forth below, subject to the payment of maintenance fees as provided by law.*

*If this application was filed prior to June 8, 1995, the term of this patent is the longer of seventeen years from the date of grant of this patent or twenty years from the earliest effective U.S. filing date of the application, subject to any statutory extension.*

*If this application was filed on or after June 8, 1995, the term of this patent is twenty years from the U.S. filing date, subject to any statutory extension. If the application contains a specific reference to an earlier filed application or applications under 35 U.S.C. 120, 121 or 365(c), the term of the patent is twenty years from the date on which the earliest application was filed, subject to any statutory extensions.*

A handwritten signature in black ink, appearing to read 'James H. Moore', is written over a horizontal line.

Director of the United States Patent and Trademark Office



US006596295B2

(12) **United States Patent**  
Naessens

(10) **Patent No.:** US 6,596,295 B2  
(45) **Date of Patent:** Jul. 22, 2003

(54) **AQUEOUS SOLUTION FOR TREATING DEGENERATIVE OR AUTOIMMUNE DISEASES AND/OR AS AN IMMUNOMODULATORY AGENT**

(76) **Inventor:** Gaston Naessens, 5260, rue mills, Rock Forest, Quebec (CA), J1N 3B6

(\* ) **Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) **Appl. No.:** 10/199,990

(22) **Filed:** Jul. 19, 2002

**Related U.S. Application Data**

(63) **Continuation of application No. PCT/CA01/00188, filed on Jan. 31, 2001.**

**Foreign Application Priority Data**

Feb. 3, 2000 (CA) ..... 2297998

(51) **Int. Cl.<sup>7</sup>** ..... A61F 13/00; A61K 9/00; A61K 33/02

(52) **U.S. Cl.** ..... 424/422; 424/434; 424/400; 424/719; 424/721

(58) **Field of Search** ..... 424/422, 434, 424/400, 719, 721

(56) **References Cited**

**FOREIGN PATENT DOCUMENTS**

GB 385 148 A 12/1932  
WO 97 05780 A 2/1997 ..... A01N/27/00

**OTHER PUBLICATIONS**

XP002167940, vol. 29, No. 3, 1896, pp. 2807-2808.

*Primary Examiner*—Thurman K. Page

*Assistant Examiner*—Robert M. Joynes

(74) *Attorney, Agent, or Firm*—Darby & Darby

(57) **ABSTRACT**

The invention concerns an aqueous solution capable of being injected by perinodular delivery or inhaled for use in the treatment of degenerative or autoimmune diseases or as immunomodulatory agent. Said solution is prepared by reacting camphor on ammonium hydroxide. The resulting product is then suspended in a saline solution. Said preparation having a basic pH is then neutralized with nitric acid. The resulting aqueous solution has pharmacological properties since it is an analogue of human cytokines, which makes it useful for treating degenerative or autoimmune diseases and/or as an immunomodulatory agent.

**6 Claims, 1 Drawing Sheet**

